Impact of a Population Genomic Screening Program on Health Behaviors Related to Familial Hypercholesterolemia Risk Reduction
Authors:
- Laney K. JonesLJLaney K. Jones
- Nan ChenNCNan Chen
- Dina A. HassenDHDina A. Hassen
- Megan N. BettsMBMegan N. Betts
- Tracey KlingerTKTracey Klinger
- Dustin N. HartzelDHDustin N. Hartzel
- David L. VeenstraDVDavid L. Veenstra
- Scott J. SpencerSSScott J. Spencer
- Susan R. SnyderSSSusan R. Snyder
- Josh F. PetersonJPJosh F. Peterson
- Victoria SchliederVSVictoria Schlieder
- Amy C. SturmASAmy C. Sturm
Open Access
- 12 July 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 15 (5) , 410-418
Abstract
Background: Limited information is available regarding clinician and participant behaviors after disclosure of genomic risk variants for familial hypercholesterolemia (FH) from a population genomic screening program. Methods: We conducted a retrospective cohort study of MyCode participants with an FH risk variant beginning 2 years before disclosure until January 16, 2019. We analyzed lipid-lowering prescriptions (clinician behavior), medication adherence (participant behavior), and LDL (low-density lipoprotein) cholesterol levels (health outcome impact) pre- and post-disclosure. Data were collected from electronic health records and claims. Results: The cohort included 96 participants of mean age 57 (22–90) years with median follow-up of 14 (range, 3–39) months. Most (90%) had a hypercholesterolemia diagnosis but no specific FH diagnosis before disclosure; 29% had an FH diagnosis post-disclosure. After disclosure, clinicians made 36 prescription changes in 38% of participants, mostly in participants who did not achieve LDL cholesterol goals pre-disclosure (81%). However, clinicians wrote prescriptions for fewer participants post-disclosure (71/96, 74.0%) compared with pre-disclosure (81/96, 84.4%); side effects were documented for most discontinued prescriptions (23/25, 92%). Among the 16 participants with claims data, medication adherence improved (proportion of days covered pre-disclosure of 70% [SD, 24.7%] to post-disclosure of 79.1% [SD, 27.3%]; P =0.05). Among the 52 (54%) participants with LDL cholesterol values both before and after disclosure, average LDL cholesterol decreased from 147 to 132 mg/dL ( P =0.003). Conclusions: Despite disclosure of an FH risk variant, nonprescribing and nonadherence to lipid-lowering therapy remained high. However, when clinicians intensified medication regimens and participants adhered to medications, lipid levels decreased.Keywords
This publication has 42 references indexed in Scilit:
- Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis SocietyEuropean Heart Journal, 2013
- Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering MedicationThe Journal of Clinical Endocrinology & Metabolism, 2012
- Patient accounts of diagnostic testing for familial hypercholesterolaemia: comparing responses to genetic and non-genetic testing methodsBMC Medical Genetics, 2012
- Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The NetherlandsAtherosclerosis, 2010
- The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side EffectsJACC, 2009
- Good and poor adherence: optimal cut-point for adherence measures using administrative claims dataCurrent Medical Research and Opinion, 2009
- SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide StudyNew England Journal of Medicine, 2008
- Self-Reported Adherence to Cholesterol-Lowering Medication in Patients with Familial Hypercholesterolaemia: The Role of Illness PerceptionsCardiovascular Drugs and Therapy, 2004
- Review of first 5 years of screening for familial hypercholesterolaemia in the NetherlandsThe Lancet, 2001
- Day-to-Day Variability of Serum Cholesterol, Triglyceride, and High-Density Lipoprotein Cholesterol LevelsArchives of internal medicine (1960), 1990